Since the start of the year, WUXI BIO (02269) has ignited two consecutive waves of bullish sentiment from major financial institutions. This follows the company's disclosure of breakthrough growth in projects within its integrated CRDMO platform at the J.P. Morgan Healthcare Conference and its better-than-expected profit alert. Prestigious investment banks including J.P. Morgan, Morgan Stanley, UBS, CLSA, Bank of America, Nomura, and China Renaissance Securities have recently assigned positive ratings such as "Overweight," "Buy," and "Outperform" to the company. They have raised their target price range for the stock to between HK$45 and HK$55, with the highest upward revision exceeding 60%.
The rationale behind these institutions broadly raising or maintaining high target prices is highly consistent. It is based on WUXI BIO's strong performance in 2025, achieving growth in both revenue and profit. High-value complex molecules like bispecific/multispecific antibodies and Antibody-Drug Conjugates (ADCs) have become the company's core growth engines. The three main business segments—Research (R), Development (D), and Manufacturing (M)—continue to drive WUXI BIO to secure more integrated projects. Furthermore, most investment banks believe the impact of current geopolitical factors on Chinese CXOs is gradually diminishing. Consequently, WUXI BIO, which is trading at a significant valuation discount compared to its peers, is expected to embark on a long-term valuation recovery.
The recent bullish stance from major institutions is fundamentally supported by the company's outstanding 2025 performance, particularly following its profit alert. In 2025, WUXI BIO achieved total revenue of RMB 21.8 billion, representing a year-on-year increase of approximately 16.7%. Its gross profit margin expanded significantly by about 5 percentage points to a high level of 46%. The company's net profit attributable to shareholders reached RMB 4.9 billion, a surge of 46.3% year-on-year. Notably, the adjusted net profit, which reflects the core operational cash-generating ability, also increased by approximately 22% year-on-year to RMB 6.6 billion.
J.P. Morgan assigned an "Overweight" rating, noting that WUXI BIO's 2025 performance forecast exceeded both market and its own expectations. The firm highlighted the 46% gross margin as being higher than the market and J.P. Morgan's expectation of "just over 40%." The institution also expressed confidence in WUXI BIO's ability to gain market share in the global biologics outsourcing market while securing more commercial-stage projects. Goldman Sachs stated that WUXI BIO's net profit and adjusted net profit for the second half of 2025 surpassed its and market expectations. The bank further suggested this was likely closely related to increased revenue from higher-margin research services.
In 2025, WUXI BIO's research services achieved new successes, with upfront and total payment amounts reaching record highs. The total potential milestone payments for research collaboration projects exceeded $4 billion. The much-watched CD3 TCE molecule collaborations continued to grow during the year. This platform has gained widespread adoption by multinational corporations and Chinese biopharmaceutical companies, including Vertex, Merck & Co., GSK, and Chia Tai Tianqing. The early strategic investment in this platform from 2016-2019 has now generated over $200 million in revenue.
Driven by the CRDMO business model and the "Follow and Win the Molecule" strategy, WUXI BIO achieved a record high of 209 new integrated projects added in 2025, bringing the total project count to 945. This further validates the company's strong business momentum and internal growth capabilities. Approximately two-thirds of the new projects were focused on bispecific antibodies and ADCs. Revenue from bispecific/multispecific antibodies grew by over 120% during the period, contributing nearly 20% of the company's total revenue and defined by WUXI BIO as its "fastest-growing and most profitable" engine.
By leveraging its technological dominance, WUXI BIO is capturing leading positions in high-growth sectors. Its deep expertise in cutting-edge areas like bispecific/multispecific antibodies, ADCs, and continuous manufacturing has built core technological barriers for complex biologics. From R&D to production, the company tackles significant technical challenges, positioning itself as a key enabler for global biologic innovation. For instance, in bispecific antibodies, WUXI BIO developed the proprietary WuXiBody platform, which addresses light chain mispairing issues. The SDArBody platform, based on camelid single-domain antibodies, allows for flexible design of bispecific/multispecific antibodies, enabling multi-dimensional optimization.
In the ADC field, WUXI BIO and its subsidiary WuXi XDC have established a trio of technologies: the WuXiDARx conjugation platform, X-LinC linker technology, and WuXiTecan payload-linker technologies. These provide customers with efficient and flexible solutions, accelerating drugs into clinical stages. In 2025, the company also launched the WuXia TrueSite targeted integration cell line platform and the WuXiHigh 2.0 high-concentration formulation platform. The former significantly enhances efficiency and stability from the foundational cell line development stage.
Daiwa Securities recently rated WUXI BIO a "Buy." Its analysis suggests that the growth in project numbers and the advantage in complex molecules like bispecific/multispecific antibodies and ADCs fully validate the robustness of the company's global footprint and technological competitiveness. Bank of America Securities and UBS hold similar views. Analyzing these institutional perspectives, against the backdrop of a sustained global R&D boom in bispecific/multispecific antibodies and ADCs, WUXI BIO, as a global leader in biologics CXO, is well-positioned. Its end-to-end CRDMO model and technological prowess in complex biologics allow it to capitalize on these hot sectors, making it a critical "infrastructure" for global biologic innovation. The high-value project pipeline is expected to further unleash the company's internal growth potential, highlighting its long-term investment value.
Beyond complex molecules, major institutions are also focusing on the further project growth potential driven by WUXI BIO's CRDMO model. Currently, the company can support approximately 200 IND filings and 20 BLA/MAA submissions annually. In 2025, it serviced 74 Phase III clinical projects and 25 commercial manufacturing projects. It completed 28 Process Performance Qualification (PPQ) projects, a 75% year-on-year increase, with 34 PPQ projects already scheduled for 2026, indicating an acceleration in commercial manufacturing business.
The collective bullish sentiment also points to WUXI BIO's unique value creation ability. As a top-tier global CRDMO, it provides customers with irreplaceable advantages in technology, capacity, and speed. This depth and breadth of value creation is key to the indispensability of its services. From a global biopharma market perspective, major pharmaceutical companies, facing patent cliffs and pricing pressures, have strong incentives to expand their pipelines. Coupled with improving financing conditions for biotechs, the upgrade of the biologics R&D industry is unstoppable, potentially propelling full-service CXOs into an accelerated growth phase.
WUXI BIO is continuously expanding its market reach by building a powerful global network. Its facilities are now spread across Asia, Europe, and North America, forming a strategic "six global poles" layout. This not only empowers clients to target global markets but also effectively balances geopolitical risks. Regarding previous investor concerns about geopolitical impacts on Chinese CXOs, Goldman Sachs noted that outsourcing remains an integral part of biopharma innovation and manufacturing strategy, and geopolitical noise has not altered the long-term economic logic supporting continued externalization. Similarly, institutions broadly observe the fading impact of geopolitical risks on the valuation of Chinese CXO firms.
J.P. Morgan indicated that WUXI BIO's share price experienced a significant correction following geopolitical concerns raised by the proposed U.S. Biosecure Act. However, as a lighter version of the bill has passed, the institution believes the largest overhanging factor for WUXI BIO has been removed. The company's growing overseas business further supports this view. Approximately half of its newly signed projects originated from the U.S., with North American revenue growing 18.3% year-on-year, accounting for 58.1% of total revenue. European market revenue grew 16.6%, representing 23.1% of total revenue.
Compared to international CDMOs, WUXI BIO's three core business drivers are fueling robust performance, with R&D segments offering higher margins, pointing to a promising outlook of high growth and high profitability. In this context, WUXI BIO's valuation, particularly on a PEG basis, has undoubtedly suffered a significant and unwarranted discount.
For WUXI BIO, even after a nearly 80% cumulative stock price increase during 2025, the company remains in an oversold state. Its recent average PE valuation remains significantly below its three-year historical center and is at the lower end of its three-year valuation range. It also trades below the industry average valuation level.
Against the backdrop of collective institutional optimism and raised target prices, the previous undervaluation of WUXI BIO has created a highly attractive pricing anchor. Based on fundamental analysis and future growth potential, WUXI BIO appears to be only at the beginning of a long-term valuation recovery. Using J.P. Morgan's target price of HK$51 as a reference, the current share price implies an upside potential of over 40%. As demand in high-growth sectors like bispecific/multispecific antibodies and ADCs continues to materialize, and the synergistic effect of the R-D-M business drivers persists, WUXI BIO's internal growth potential is expected to be further unleashed. The company projects 13%-17% year-on-year revenue growth for 2026, suggesting its long-term investment value can be consistently realized, with a high degree of certainty for valuation recovery.
Comments